B-CELL NON HODGKIN LYMPHOMA
Clinical trials for B-CELL NON HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new B-CELL NON HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for B-CELL NON HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New combo therapy offers hope for Tough-to-Treat lymphoma
Disease control OngoingThis study tests a new treatment for people with relapsed or refractory B-cell non-Hodgkin lymphoma, a type of blood cancer that has not responded to standard therapies. The treatment combines two immune-based approaches: a bispecific antibody and CAR-T cells, aiming to boost the…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 26, 2026 09:00 UTC
-
Can anakinra stop CAR-T's dangerous side effects?
Disease control OngoingThis study tests whether the drug anakinra can prevent or reverse severe side effects from CAR-T cell therapy, a treatment for certain blood cancers. About 62 adults with relapsed B-cell cancers will receive anakinra alongside their CAR-T treatment. The goal is to reduce serious …
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 08:57 UTC
-
New combo therapy shows promise for tough lymphoma
Disease control OngoingThis early-phase study tests whether adding the drug acalabrutinib to a type of immune cell therapy (CAR T-cells) can safely treat B-cell lymphoma, a cancer of the immune system. About 23 adults with certain aggressive or slow-growing lymphomas will receive the combination. The g…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated May 26, 2026 08:56 UTC
-
New drug N-803 tested to boost CAR T-Cell results in lymphoma patients
Disease control TerminatedThis early-phase study aimed to see if the drug N-803 is safe for people with B-cell non-Hodgkin lymphoma who have already received CAR T-cell therapy. It planned to enroll adults whose cancer had responded partially or completely to CAR T-cells. The main goal was to find the bes…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: University of Utah • Aim: Disease control
Last updated May 26, 2026 08:54 UTC
-
New drug cocktail aims to stop lymphoma relapse after powerful treatments
Disease control OngoingThis study tests whether combining two drugs, pembrolizumab and tazemetostat, can help prevent aggressive B-cell non-Hodgkin lymphoma from returning in patients who have already had a stem cell transplant or CAR T-cell therapy. About 32 adults will receive the drug combination. T…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Northwestern University • Aim: Disease control
Last updated May 19, 2026 11:47 UTC
-
Blood test may forecast lymphoma prognosis
Knowledge-focused OngoingThis study looks at whether changes in tumor DNA found in the blood can help predict how B-cell non-Hodgkin lymphoma will progress. Researchers will collect blood samples from 60 patients before and during treatment to see if DNA levels relate to survival or response. This is an …
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Knowledge-focused
Last updated May 26, 2026 08:55 UTC
-
Blood test may outsmart scans in spotting lymphoma return
Knowledge-focused OngoingThis study looks at whether a simple blood test can find signs of lymphoma coming back after chemotherapy, possibly before CT scans do. About 500 adults with aggressive B-cell Non-Hodgkin lymphoma will give blood samples after treatment. The goal is to see if this test could repl…
Matched conditions: B-CELL NON HODGKIN LYMPHOMA
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated May 04, 2026 16:22 UTC